NICE Still Opposes Adding Fampyra to NHS for England

NICE Still Opposes Adding Fampyra to NHS for England

314599

NICE Still Opposes Adding Fampyra to NHS for England

The National Institute for Health and Care Excellence (NICE) in England is set to again recommend against adding Fampyra (fampridine) to the list of medications available to multiple sclerosis (MS) patients with walking difficulties through the country’s national health service (NHS). The poor cost-effectiveness of Fampyra — sold as Ampyra in the U.S. and with generics also available — has been cited as NICE’s persistent concern (since 2014) in its draft guidance for the management of…

You must be logged in to read/download the full post.